These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 23146533)
1. Sirolimus for the treatment of Kaposi sarcoma after renal transplantation: a series of 10 cases. Yaich S; Charfeddine K; Zaghdane S; El Aoud N; Jarraya F; Kharrat M; Hachicha J Transplant Proc; 2012 Nov; 44(9):2824-6. PubMed ID: 23146533 [TBL] [Abstract][Full Text] [Related]
3. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion. Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436 [TBL] [Abstract][Full Text] [Related]
4. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508 [TBL] [Abstract][Full Text] [Related]
5. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies. Boratyńska M; Watorek E; Smolska D; Patrzałek D; Klinger M Transplant Proc; 2007 Nov; 39(9):2736-9. PubMed ID: 18021973 [TBL] [Abstract][Full Text] [Related]
6. Regression of Kaposi's sarcoma in renal graft recipients after conversion to sirolimus treatment. Zmonarski SC; Boratyńska M; Rabczyński J; Kazimierczak K; Klinger M Transplant Proc; 2005 Mar; 37(2):964-6. PubMed ID: 15848592 [TBL] [Abstract][Full Text] [Related]
7. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation. Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109 [TBL] [Abstract][Full Text] [Related]
8. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy. Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606 [TBL] [Abstract][Full Text] [Related]
9. Clinical features and course of Kaposi's sarcoma in kidney transplant patients: report of 13 cases. Montagnino G; Bencini PL; Tarantino A; Caputo R; Ponticelli C Am J Nephrol; 1994; 14(2):121-6. PubMed ID: 8080004 [TBL] [Abstract][Full Text] [Related]
10. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation. Manuelli M; De Luca L; Iaria G; Tatangelo P; Sforza D; Perrone L; Bellini MI; Angelico R; Anselmo A; Tisone G Transplant Proc; 2010 May; 42(4):1314-6. PubMed ID: 20534289 [TBL] [Abstract][Full Text] [Related]
11. Successful treatment of post-renal transplant gastric and pulmonary Kaposi's sarcoma with conversion to rapamycin treatment. Charfi S; Krichen-Makni S; Yaich S; Makni H; Khabir A; Amouri A; Charfeddine K; Hachicha J; Sellami-Boudawara T Saudi J Kidney Dis Transpl; 2007 Nov; 18(4):617-20. PubMed ID: 17951954 [TBL] [Abstract][Full Text] [Related]
12. Combination treatment of low dose Anti-Thymocyte Globulin (ATG), Rituximab and high dose Sirolimus as induction agents in immune-conditioned recipients. Ravichandran P; Natrajan T; Jaganathan R Int Immunopharmacol; 2006 Dec; 6(13-14):1973-6. PubMed ID: 17161350 [TBL] [Abstract][Full Text] [Related]
13. Conversion to everolimus in kidney transplant recipients: to believe or not believe? Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007 [TBL] [Abstract][Full Text] [Related]
14. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF; Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978 [TBL] [Abstract][Full Text] [Related]
15. Early sirolimus therapy in renal transplant recipients at high risk: is it justified? Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Al-Waheeb S; Hasaneen H; Awadain WH; Nawas KM; El-Sayed A; Said T; Nair MP; Nampoory MR Transplant Proc; 2009 Sep; 41(7):2784-8. PubMed ID: 19765435 [TBL] [Abstract][Full Text] [Related]
16. Regression of post-transplant Kaposi's sarcoma using sirolimus. Kolhe N; Mamode N; Van der Walt J; Pattison J Int J Clin Pract; 2006 Nov; 60(11):1509-12. PubMed ID: 16787440 [TBL] [Abstract][Full Text] [Related]
17. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy. Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C Pediatr Transplant; 2006 Aug; 10(5):565-9. PubMed ID: 16856992 [TBL] [Abstract][Full Text] [Related]
18. Outcome of Kaposi's sarcoma and graft following discontinuation of immunosuppressive drugs in renal transplant recipients. Firoozan A; Hosseini Moghaddam SM; Einollahi B; Pour-Reza-Gholi F; Nafar M; Basiri A; Ebrahimi-Rad R Transplant Proc; 2005 Sep; 37(7):3061-4. PubMed ID: 16213305 [TBL] [Abstract][Full Text] [Related]